DCM
ABUS icon

DAFNA Capital Management’s Arbutus Biopharma ABUS Stock Holding History

DAFNA Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-246,900
Closed -$884K – 88
2019
Q1 		$884K Hold
246,900
– – 0.38% 56
2018
Q4 		$946K Buy
+246,900
New +$1.22M 0.47% 50
2017
Q1 		– Sell
-234,000
Closed -$573K – 73
2016
Q4 		$573K Buy
+234,000
New +$681K 0.5% 51
2016
Q3 		– Sell
-75,000
Closed -$261K – 77
2016
Q2 		$261K Sell
75,000
-40,230
-35% -$170K 0.21% 70
2016
Q1 		$476K Buy
+115,230
New +$412K 0.41% 65

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAFNA Capital Management's ABUS Position: Q2 2019 in Review

DAFNA Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2019, closing a stake of 246,900 shares — an estimated $884K sold.

DAFNA Capital Management first reported a position in ABUS in Q1 2016 and held it in 5 quarters. The position peaked at $946K in Q4 2018. 62 funds tracked by Wall St. Rank hold ABUS as of Q2 2019.

  • DAFNA Capital Management reported no remaining Arbutus Biopharma position as of Q2 2019 after selling out during the quarter.
  • DAFNA Capital Management sold 246,900 Arbutus Biopharma shares in Q2 2019, an estimated $884K.
  • DAFNA Capital Management first reported a position in Arbutus Biopharma in Q1 2016 and held it in 5 quarters.
  • DAFNA Capital Management's Arbutus Biopharma position peaked at $946K in Q4 2018.
  • 62 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2019.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.